FDA Approves TADALAFIL — NorthStar RxLLC

NorthStar RxLLC announced today the FDA approval of Tadafil, a generic version of tadalafil with an ANDA 208934, to support the market with bioequivalent alternatives to branded erectile dysfunction treatments. This commercial launch introduces a lower-cost competitor into the established ED therapeutic class, compelling branded franchise holders to adjust their pricing strategies to maintain market share.